利用通用 2009 年 H1N1 血凝素 (HA) 和神经氨酸酶 (NA) 腺病毒载体疫苗预防流感病毒脱落和保护免受致死性 H1N1 挑战。
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.
机构信息
Etubics Corporation, Seattle, WA 98199, USA.
出版信息
Vaccine. 2011 Sep 16;29(40):7020-6. doi: 10.1016/j.vaccine.2011.07.073. Epub 2011 Aug 5.
Abstract
Vaccines against emerging pathogens such as the 2009 H1N1 pandemic virus can benefit from current technologies such as rapid genomic sequencing to construct the most biologically relevant vaccine. A novel platform (Ad5 [E1-, E2b-]) has been utilized to induce immune responses to various antigenic targets. We employed this vector platform to express hemagglutinin (HA) and neuraminidase (NA) genes from 2009 H1N1 pandemic viruses. Inserts were consensuses sequences designed from viral isolate sequences and the vaccine was rapidly constructed and produced. Vaccination induced H1N1 immune responses in mice, which afforded protection from lethal virus challenge. In ferrets, vaccination protected from disease development and significantly reduced viral titers in nasal washes. H1N1 cell mediated immunity as well as antibody induction correlated with the prevention of disease symptoms and reduction of virus replication. The Ad5 [E1-, E2b-] should be evaluated for the rapid development of effective vaccines against infectious diseases.
摘要
针对 2009 年 H1N1 大流行病毒等新兴病原体的疫苗可以受益于当前的技术，如快速基因组测序，以构建最具生物学相关性的疫苗。一种新型平台（Ad5 [E1-，E2b-]）已被用于诱导针对各种抗原靶标的免疫反应。我们利用该载体平台表达来自 2009 年 H1N1 大流行病毒的血凝素 (HA) 和神经氨酸酶 (NA) 基因。插入物是根据病毒分离株序列设计的共识序列，疫苗被快速构建和生产。疫苗接种可诱导小鼠产生 H1N1 免疫应答，从而提供对致死性病毒攻击的保护。在雪貂中，疫苗接种可预防疾病发展，并显著降低鼻洗液中的病毒滴度。H1N1 细胞介导的免疫和抗体诱导与预防疾病症状和减少病毒复制相关。Ad5 [E1-，E2b-] 应该针对传染病的快速开发有效的疫苗进行评估。
相似文献
1
Prevention of influenza virus shedding and protection from lethal H1N1 challenge using a consensus 2009 H1N1 HA and NA adenovirus vector vaccine.利用通用 2009 年 H1N1 血凝素 (HA) 和神经氨酸酶 (NA) 腺病毒载体疫苗预防流感病毒脱落和保护免受致死性 H1N1 挑战。
Vaccine. 2011 Sep 16;29(40):7020-6. doi: 10.1016/j.vaccine.2011.07.073. Epub 2011 Aug 5.
2
Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.神经氨酸酶抑制抗体滴度与对同一神经氨酸酶亚型的异源流感病毒株的保护作用相关。
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.01006-18. Print 2018 Sep 1.
3
Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.接种表达神经氨酸酶的重组副流感病毒5可抵御同源和异源流感病毒攻击。
J Virol. 2017 Nov 14;91(23). doi: 10.1128/JVI.01579-17. Print 2017 Dec 1.
4
Vaccine-induced NA immunity decreases viral shedding, but does not disrupt chains of airborne transmission for the 2009 pandemic H1N1 virus in ferrets.疫苗诱导的 NA 免疫可减少病毒脱落，但不能中断 2009 年大流行 H1N1 病毒在雪貂中的空气传播链。
mBio. 2024 Oct 16;15(10):e0216124. doi: 10.1128/mbio.02161-24. Epub 2024 Sep 9.
5
Immune effects against influenza A virus and a novel DNA vaccine with co-expression of haemagglutinin- and neuraminidase-encoding genes.针对甲型流感病毒的免疫效应以及一种共表达血凝素编码基因和神经氨酸酶编码基因的新型DNA疫苗。
J Med Microbiol. 2009 Jul;58(Pt 7):845-854. doi: 10.1099/jmm.0.006825-0. Epub 2009 Jun 4.
6
Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.重组可溶性、多聚体的 HA 和 NA 对豚鼠具有不同类型的保护作用，可预防大流行的猪源 2009 年 A(H1N1)流感病毒感染。
J Virol. 2010 Oct;84(19):10366-74. doi: 10.1128/JVI.01035-10. Epub 2010 Aug 4.
7
A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.一种缺乏糖蛋白基因并表达流感病毒血凝素和神经氨酸酶的有活力的重组弹状病毒是一种有效的流感疫苗。
J Virol. 2015 Mar;89(5):2820-30. doi: 10.1128/JVI.03246-14. Epub 2014 Dec 24.
8
A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.一种 VLP 疫苗可诱导针对 H5N1 和 H1N1 亚型流感病毒的广谱交叉保护抗体免疫。
PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.
9
Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.新型改良安卡拉痘苗病毒（MVA）载体疫苗在小鼠体内对多种流感病毒亚型产生的交叉保护免疫。
Vaccine. 2013 Apr 3;31(14):1848-55. doi: 10.1016/j.vaccine.2013.01.038. Epub 2013 Feb 1.
10
Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin.集中的流感血凝素可预防不同的甲型 H1N1 流感病毒。
PLoS One. 2011 Mar 28;6(3):e18314. doi: 10.1371/journal.pone.0018314.
引用本文的文献
1
Development of NP-Based Universal Vaccine for Influenza A Viruses.基于纳米颗粒的甲型流感病毒通用疫苗的研发。
Vaccines (Basel). 2024 Feb 2;12(2):157. doi: 10.3390/vaccines12020157.
2
A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice.一种表达融合蛋白表位的嵌合流感病毒疫苗可诱导小鼠免受人偏肺病毒攻击。
Front Microbiol. 2023 Dec 14;13:1012873. doi: 10.3389/fmicb.2022.1012873. eCollection 2022.
3
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.双抗原 COVID-19 疫苗经皮接种与口服加强剂可保护非人灵长类动物免受 SARS-CoV-2 挑战。
Front Immunol. 2021 Sep 16;12:729837. doi: 10.3389/fimmu.2021.729837. eCollection 2021.
4
The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses.神经氨酸酶作为鼻腔疫苗抗原增加对流感病毒交叉保护的潜力。
J Virol. 2021 Sep 27;95(20):e0118021. doi: 10.1128/JVI.01180-21. Epub 2021 Aug 11.
5
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.腺病毒载体疫苗可完全预防哈特利豚鼠致命性拉沙热挑战。
Vaccine. 2019 Oct 23;37(45):6824-6831. doi: 10.1016/j.vaccine.2019.09.030. Epub 2019 Sep 24.
6
Decreased Vector Gene Expression from E2b Gene-Deleted Adenovirus Serotype 5 Vaccines Intensifies Proinflammatory Immune Responses.来自E2b基因缺失的5型腺病毒疫苗的载体基因表达降低会增强促炎免疫反应。
Clin Vaccine Immunol. 2017 Jun 5;24(6). doi: 10.1128/CVI.00061-17. Print 2017 Jun.
7
Viral vector-based influenza vaccines.基于病毒载体的流感疫苗。
Hum Vaccin Immunother. 2016 Nov;12(11):2881-2901. doi: 10.1080/21645515.2016.1210729. Epub 2016 Jul 25.
8
A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates.一种基于复制缺陷型人5型腺病毒的三价疫苗可使小鼠和非人灵长类动物获得针对鼠疫的完全保护。
Clin Vaccine Immunol. 2016 Jul 5;23(7):586-600. doi: 10.1128/CVI.00150-16. Print 2016 Jul.
9
The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.作为一种免疫疗法的、靶向三种肿瘤抗原的新型重组腺病毒疫苗组合的产生与分析。
Oncotarget. 2015 Oct 13;6(31):31344-59. doi: 10.18632/oncotarget.5181.
10
Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer.对一项1/2期试验的扩展评估，该试验涉及晚期结直肠癌患者接种新一代Ad5 [E1-，E2b-]-CEA(6D)疫苗后的剂量、安全性、免疫原性和总生存期。
Cancer Immunol Immunother. 2015 Aug;64(8):977-87. doi: 10.1007/s00262-015-1706-4. Epub 2015 May 9.
本文引用的文献
1
An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice.Ad5[E1-, E2b-]-HER2/neu 载体在 Ad5 免疫小鼠中诱导免疫反应并抑制 HER2/neu 表达肿瘤的进展。
Cancer Gene Ther. 2011 May;18(5):326-35. doi: 10.1038/cgt.2010.82. Epub 2011 Jan 14.
2
A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.复制缺陷型重组腺病毒 5 型疫苗表达埃博拉病毒 GP，在健康成年人中是安全和有免疫原性的。
Vaccine. 2010 Dec 16;29(2):304-13. doi: 10.1016/j.vaccine.2010.10.037. Epub 2010 Oct 27.
3
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.展示所有主要免疫决定簇的拉沙病毒样颗粒，可用作拉沙热出血热的候选疫苗。
Virol J. 2010 Oct 20;7:279. doi: 10.1186/1743-422X-7-279.
4
Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.载体选择决定了针对安哥拉马尔堡病毒的基因疫苗在非人类灵长类动物中的免疫原性和效力。
J Virol. 2010 Oct;84(19):10386-94. doi: 10.1128/JVI.00594-10. Epub 2010 Jul 21.
5
Influenza: the once and future pandemic.流感：曾今及未来的大流行疾病。
Public Health Rep. 2010 Apr;125 Suppl 3(Suppl 3):16-26.
6
2009 H1N1 virus transmission and outbreaks.2009年甲型H1N1流感病毒的传播与暴发。
N Engl J Med. 2010 Jun 10;362(23):2221-3. doi: 10.1056/NEJMe1004468.
7
Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA.采用新型腺病毒载体 Ad5[E1-，E2b-]-CEA 进行抗肿瘤免疫治疗，可克服对腺病毒的免疫。
Cancer Immunol Immunother. 2010 Jul;59(7):1131-5. doi: 10.1007/s00262-010-0847-8. Epub 2010 Apr 2.
8
Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages.季节性和大流行性 H1N1 流感中对奥司他韦的耐药性选择和谱系的广泛共同传播。
Int J Health Geogr. 2010 Feb 24;9:13. doi: 10.1186/1476-072X-9-13.
9
Genetic stability and linkage analysis of the 2009 Influenza A(H1N1) virus based on sequence homology.基于序列同源性的 2009 年甲型 H1N1 流感病毒的遗传稳定性和连锁分析。
Arch Virol. 2009;154(12):1883-90. doi: 10.1007/s00705-009-0526-2. Epub 2009 Oct 27.
10
Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity.新型5型腺病毒疫苗平台可诱导针对HIV-1 Gag、Pol、Nef的细胞免疫，尽管存在5型腺病毒免疫力。
Vaccine. 2009 Oct 30;27(46):6394-8. doi: 10.1016/j.vaccine.2009.06.028. Epub 2009 Jun 24.
Zotero 插件